

Lost in Translation: the gap between discovery research and product development

Dr Ian Nisbet, Co-Founder and Corporate Advisor, Cartherics

Ian has over 30 years of product development, business development and project management experience in the biotechnology sector, both in Australia and the United States. He has worked at an executive or board level with companies developing products across a range of therapeutic areas (including oncology, inflammatory disease, diabetes, Alzheimer's Disease) and modalities (including small molecules, antibodies, cellular therapies and vaccines). He played a leadership role in the development of two FDA-approved oncology drugs: VELCADE (bortezomib) and SYNRIBO (omacetaxine). Ian currently serves as Corporate Advisor to Cartherics Pty Ltd, CEO of Cancure Pty Ltd and Chair of VivaZome Pty Ltd. He also acts as a director or advisor to several biotechnology companies, including three US companies undertaking product development in Australia. Ian received his BSc in microbiology and biochemistry from the University of Melbourne and his PhD in molecular biology from Monash University. He is also a graduate of the Advanced Management Program from the Melbourne Business School at the University of Melbourne and is a member of the Australian Institute of Company Directors.

Dr Tim Oldham, Executive Leader, Tijan Ventures

Tim has more than 15 years of pharmaceuticals and life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is the Executive Leader of Tijan Ventures, a business focussed on launching and growing life sciences companies through strategic advisory and interim, executive and non-executive leadership services, with a particular focus on regenerative medicine. He was CEO and Managing Director of Cell Therapies Pty Ltd (2014-2017), a leading Asia Pacific provider of manufacturing and distribution for cell-based therapeutics. Tim was President of Asia Pacific for Hospira Inc. (2007 to 2012), having held a variety of senior management roles with Mayne Pharma in Europe (2002 to 2007) prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies. Prior to this, Tim was an engagement manager with McKinsey & Co (1997 to 2001). He is a director of Acrux Ltd (ASX:ACR) and has been a Director of Respiro Ltd (ASX: RSH). Tim has been chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine, a Director of the Generic Medicines Industry Association and is a current member of AusBiotech's Regenerative Medicine Advisory Group.



DATE

THURS 13
SEPTEMBER

TIME

12.00PM – 1.00PM

LOCATION

TRF BUILDING
LEVEL 2, SEMINAR
ROOMS 1 AND 2